DrugPatentWatch Database Preview
Details for Patent: 8,466,159
» See Plans and Pricing
Which drugs does patent 8,466,159 protect, and when does it expire?
Patent 8,466,159 protects VIEKIRA XR and VIEKIRA PAK (COPACKAGED) and is included in two NDAs.
This patent has fifty-four patent family members in twenty-eight countries.
Summary for Patent: 8,466,159
| Title: | Methods for treating HCV |
| Abstract: | The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. |
| Inventor(s): | Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Podsadecki; Thomas J. (Chicago, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL) |
| Assignee: | AbbVie Inc. (North Chicago, IL) |
| Application Number: | 13/603,022 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,466,159 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,466,159
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | Start Trial | Start Trial | TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN. | Start Trial | ||||
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN. | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,466,159
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 088463 | Start Trial | |||
| Austria | 514003 | Start Trial | |||
| Australia | 2013201406 | Start Trial | |||
| Brazil | 112014006314 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
